Author: Suwannarach, Nakarin; Kumla, Jaturong; Sujarit, Kanaporn; Pattananandecha, Thanawat; Saenjum, Chalermpong; Lumyong, Saisamorn
Title: Natural Bioactive Compounds from Fungi as Potential Candidates for Protease Inhibitors and Immunomodulators to Apply for Coronaviruses Cord-id: i6klf963 Document date: 2020_4_14
ID: i6klf963
Snippet: The inhibition of viral protease is an important target in antiviral drug discovery and development. To date, protease inhibitor drugs, especially HIV-1 protease inhibitors, have been available for human clinical use in the treatment of coronaviruses. However, these drugs can have adverse side effects and they can become ineffective due to eventual drug resistance. Thus, the search for natural bioactive compounds that were obtained from bio-resources that exert inhibitory capabilities against HI
Document: The inhibition of viral protease is an important target in antiviral drug discovery and development. To date, protease inhibitor drugs, especially HIV-1 protease inhibitors, have been available for human clinical use in the treatment of coronaviruses. However, these drugs can have adverse side effects and they can become ineffective due to eventual drug resistance. Thus, the search for natural bioactive compounds that were obtained from bio-resources that exert inhibitory capabilities against HIV-1 protease activity is of great interest. Fungi are a source of natural bioactive compounds that offer therapeutic potential in the prevention of viral diseases and for the improvement of human immunomodulation. Here, we made a brief review of the current findings on fungi as producers of protease inhibitors and studies on the relevant candidate fungal bioactive compounds that can offer immunomodulatory activities as potential therapeutic agents of coronaviruses in the future.
Search related documents:
Co phrase search for related documents- active site and acute respiratory: 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25
- active site and acute respiratory syndrome: 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25
- active site and adaptive innate: 1, 2
- active site and lopinavir ritonavir: 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11
- active site and low molecular weight: 1, 2, 3, 4
- active substance and acute respiratory: 1, 2, 3, 4
- active substance and acute respiratory syndrome: 1, 2
- active substance and adaptive innate: 1
- activity structure and acute ards respiratory distress syndrome: 1, 2
- activity structure and acute respiratory: 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25
- activity structure and acute respiratory syndrome: 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25
- activity structure and adaptive innate: 1, 2, 3
- activity structure and lopinavir ritonavir: 1
- activity structure and low molecular weight: 1
- acute ali lung injury and adaptive innate: 1, 2, 3
- acute ali lung injury and adaptive innate immune response: 1, 2
- acute ali lung injury and long chain: 1
- acute ali lung injury and lopinavir ritonavir: 1
- acute ali lung injury and low molecular weight: 1, 2
Co phrase search for related documents, hyperlinks ordered by date